V

Vifor Pharma AG
SIX:VIFN

Watchlist Manager
Vifor Pharma AG
SIX:VIFN
Watchlist
Price: 166.15 CHF 0.48%
Market Cap: 10.8B CHF

Relative Value

VIFN price has not been updated for more than 1 month. This may indicate that the stock has been delisted.

There is not enough data to reliably calculate the relative value of VIFN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VIFN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
6.2
Median 5Y
6.2
Industry
2.6
Forward
5.7
vs History
vs Industry
Median 3Y
74.7
Median 5Y
74.7
Industry
21.4
Forward
44.9
vs History
vs Industry
Median 3Y
20.5
Median 5Y
20.5
Industry
16.4
vs History
vs Industry
Median 3Y
38
Median 5Y
38
Industry
22.8
vs History
vs Industry
Median 3Y
3.1
Median 5Y
3.1
Industry
2.2
vs History
vs Industry
Median 3Y
5.7
Median 5Y
5.7
Industry
2.9
Forward
5.2
vs History
vs Industry
Median 3Y
9.2
Median 5Y
9.2
Industry
5.5
vs History
vs Industry
Median 3Y
14.8
Median 5Y
14.8
Industry
13
Forward
15.6
vs History
vs Industry
Median 3Y
28.2
Median 5Y
28.2
Industry
16.5
Forward
24.3
vs History
vs Industry
Median 3Y
18.8
Median 5Y
18.8
Industry
15.6
vs History
vs Industry
Median 3Y
32.1
Median 5Y
32.1
Industry
18.7
vs History
vs Industry
Median 3Y
2.5
Median 5Y
2.5
Industry
1.9

Multiples Across Competitors

VIFN Competitors Multiples
Vifor Pharma AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Vifor Pharma AG
SIX:VIFN
10.8B CHF 6.1 74.7 14.7 28.2
US
Eli Lilly and Co
NYSE:LLY
985.1B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.6B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
207.5B GBP 4.8 29.9 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
267.2B USD 4.2 14 10 11.8
CH
Novartis AG
SIX:NOVN
208.2B CHF 4.7 18.3 11.6 15
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.9 14.8 10.3 12
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
143.1B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
CH
V
Vifor Pharma AG
SIX:VIFN
Average P/E: 29.6
74.7
31%
2.4
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14
15%
0.9
CH
Novartis AG
SIX:NOVN
18.3
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.8
3%
4.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
V
Vifor Pharma AG
SIX:VIFN
Average EV/EBITDA: 401
14.7
6%
2.5
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
V
Vifor Pharma AG
SIX:VIFN
Average EV/EBIT: 1 714.6
28.2
16%
1.8
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.8
8%
1.5
CH
Novartis AG
SIX:NOVN
15
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
12
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5